2019/10/01 by Diane S. Aschenbrenner · 1 citation
Medicine · #Blood pressure #Drug #Gynecology #Hormonal and reproductive studies #Human sexuality #Hypoactive sexual desire disorder #Internal medicine #Medicine #Nausea #Pharmacology #Sexual desire #Sexual dysfunction #Sexual function and dysfunction studies #Urticaria and Related Conditions
paper · doi:10.1097/01.naj.0000586140.72896.b0
openalex publication_date 2019/10/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/05/21
Bremelanotide (Vyleesi) is now approved for the treatment of generalized hypoactive sexual desire disorder in premenopausal women. The drug may transiently increase blood pressure, induce focal hyperpigmentation, and produce nausea. Nurses and NPs should confirm that a patient's blood pressure is under control prior to starting bremelanotide.